CASTOR

Subgroup analyses of CASTOR & POLLUX in R/R multiple myeloma

Meta-analysis of cilta-cel in patients with R/R multiple myeloma

POLLUX & CASTOR analysis: MRD- with dara-combination regimens

CD38: a promising target for multiple myeloma antibody therapy

The next five years of multiple myeloma treatment

Therapeutic options for hard to treat R/R myeloma

Cytogenetic risk & the impact of daratumumab in myeloma

The definitive guide to multiple myeloma at ASH 2018: part I

Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma

Carfilzomib for relapsed multiple myeloma: clinical trial updates

The importance of MRD status in MM

CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM

Promising results for daratumumab in the front line setting

Unprecedented clinical trial results for MM

How effective are monoclonal antibodies at improving overall survival?

Effective antibody therapy and updates from the POLLUX and CASTOR trials